This Cancer Center Support Grant application from the University of Pittsburgh Cancer Institute, an NCI-designated Comprehensive Cancer Center, seeks support for years 22-26. The UPCI is organized as a matrix center that integrates cancer research, clinical care, and cancer outreach across the University of Pittsburgh and its affiliated health system, UPMC. The UPCI includes 348 members from 37 academic departments who have come together to work to reduce the burden of cancer through cancer-related basic, translational, clinical, behavioral, epidemiological, prevention and control research. Total annual extramural cancer research funding (direct costs) to UPCI was $109.5 million (peer-reviewed $95M, non-peer-reviewed $14.5M) on October 1, 2009 of which $42.5M was received from the National Cancer Institute. The commitment of UPCI to transdisciplinary cancer research is exemplified by the fact that its members lead three SPORE grants (lung, head and neck, and skin cancers), eight cancer-focused P01s, two Early Detection Research Network grants, and a phase I U01. The impact of the cancer research driven by UPCI and its members can be seen in the more than 4,400 unique publications by UPCI investigators from 2004-2009 of which 45% represent collaborative efforts (17% intra-programmatic, 20% inter-programmatic, and 8% both). The integration of investigators at the main University of Pittsburgh campus with clinicians from a unique clinical care network encompassing about 40 UPMC community cancer centers across Western Pennsylvania has enabled enhanced patient access to clinical trials throughout our catchment area in a highly productive way. In 2008 a total of 11,484 patients were entered in the cancer registry. During that same year 1,158 and 2,508 patients entered interventional and non-interventional clinical trials, respectively. It is noteworthy that in 2008 30% of accruals to interventional trials were to investigator-initiated trials and 40% of accruals to interventional trials took place at UPMC community cancer centers. This renewal application requests support for twelve scientific research Programs, fifteen Shared Facilities, Protocol-Specific Research Support, Protocol Review and Monitoring System, planning and evaluation activities, developmental funds, senior leadership, staff investigators, and administration.

Public Health Relevance

UPCI is a comprehensive Cancer Center focused on cancer research, education, and care. UPCI laboratory and clinical investigators work closely together to identify improved approaches for cancer prevention, diagnosis and treatment with the common goal of reducing the burden of cancer and improving cancer care for patients who are diagnosed with this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA047904-26S2
Application #
8795826
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (M1))
Program Officer
Marino, Michael A
Project Start
1997-09-10
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$72,734
Indirect Cost
$25,504
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Correa, Andres F; Toussi, Amir; Amin, Milon et al. (2018) Small Renal Masses in Close Proximity to the Collecting System and Renal Sinus Are Enriched for Malignancy and High Fuhrman Grade and Should Be Considered for Early Intervention. Clin Genitourin Cancer 16:e729-e733
Wang, Yi-Jun; Fletcher, Rochelle; Yu, Jian et al. (2018) Immunogenic effects of chemotherapy-induced tumor cell death. Genes Dis 5:194-203
Bakkenist, Christopher J; Lee, James J; Schmitz, John C (2018) ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer. Clin Colorectal Cancer 17:255-257
Low, Carissa A; Bovbjerg, Dana H; Ahrendt, Steven et al. (2018) Fitbit step counts during inpatient recovery from cancer surgery as a predictor of readmission. Ann Behav Med 52:88-92
Tasdemir, Nilgun; Bossart, Emily A; Li, Zheqi et al. (2018) Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res 78:6209-6222
Mazharuddin, Samir; Chattopadhyay, Anuja; Levy, Moshe Y et al. (2018) IRF2BP2-RARA t(1;17)(q42.3;q21.2) APL blasts differentiate in response to all-trans retinoic acid. Leuk Lymphoma 59:2246-2249
Basudan, Ahmed; Priedigkeit, Nolan; Hartmaier, Ryan J et al. (2018) Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Mol Cancer Res :
Beumer, Jan H; Chu, Edward; Allegra, Carmen et al. (2018) Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. Clin Pharmacol Ther :
Song, Xinxin; Zhu, Shan; Chen, Pan et al. (2018) AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc- Activity. Curr Biol 28:2388-2399.e5
Leng, Shuguang; Diergaarde, Brenda; Picchi, Maria A et al. (2018) Gene Promoter Hypermethylation Detected in Sputum Predicts FEV1 Decline and All-Cause Mortality in Smokers. Am J Respir Crit Care Med 198:187-196

Showing the most recent 10 out of 1187 publications